India is growing in importance as a hub for biopharmaceutical manufacturing, particularly in the context of the proposed Biosecure Act in the United States. The Act aims to restrict U.S. biotech companies from working with Chinese firms, potentially driving more business towards Indian contract development and manufacturing organizations (CDMOs). A...
Biocon scouts R&D pact after General Electric unit takes stake in research division
Bolstered by positive new data on its insulin program and growing profits, India's Biocon also won a big financial backer for its R&D outsourcing arm as it prepares to take the unit public. GE Capital has agreed to pay $23 million for a 7.7% stake in Syngene, which handles contract...